93 related articles for article (PubMed ID: 7371363)
1. Dependence liability of two antidiarrheals, nufenoxole and loperamide.
Korey A; Zilm DH; Sellers EM
Clin Pharmacol Ther; 1980 May; 27(5):659-64. PubMed ID: 7371363
[TBL] [Abstract][Full Text] [Related]
2. Nufenoxole, a new antidiarrhoeal agent, inhibits fluid secretion in the human jejunum.
Moriarty KJ; Rolston DD; Kelly MJ; Shield M; Clark ML
Gut; 1985 Jan; 26(1):75-80. PubMed ID: 2578119
[TBL] [Abstract][Full Text] [Related]
3. Abuse potential of loperamide.
Jaffe JH; Kanzler M; Green J
Clin Pharmacol Ther; 1980 Dec; 28(6):812-9. PubMed ID: 7438696
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics of nufenoxole in healthy human subjects.
Brownsill RD; Hiley MP; Vose CW; Steiner JA; Stafford JE; McAllister A; Rose DA; Gerry N
Xenobiotica; 1987 Nov; 17(11):1373-7. PubMed ID: 3433806
[TBL] [Abstract][Full Text] [Related]
5. [Physical dependence on loperamide hydrochloride in mice and rats].
Nakamura H; Ishii K; Yokoyama Y; Motoyoshi S; Suzuki K; Sekine Y; Hashimoto M; Shimizu M
Yakugaku Zasshi; 1982 Nov; 102(11):1074-85. PubMed ID: 6892112
[No Abstract] [Full Text] [Related]
6. Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test.
Basilisco G; Bozzani A; Camboni G; Recchia M; Quatrini M; Conte D; Penagini R; Bianchi PA
Gut; 1985 Jul; 26(7):700-3. PubMed ID: 4018633
[TBL] [Abstract][Full Text] [Related]
7. Long-term survey of the treatment of diarrhoea with loperamide.
Mainguet P; Fiasse R; Turine JB
Digestion; 1977; 16(1-2):69-76. PubMed ID: 355023
[TBL] [Abstract][Full Text] [Related]
8. Different actions of 2 antidiarrheal agents, lidamidine and loperamide, on motility of the isolated cat colon muscle.
Wienbeck M; Bohn M
Z Gastroenterol; 1985 Apr; 23(4):175-82. PubMed ID: 4060808
[TBL] [Abstract][Full Text] [Related]
9. Antidiarrheal and central nervous system activities of SC-27166 (2-[3 - 5 - methyl - 1, 3, 4 - oxadiazol - 2 - yl) - 3, 3 - diphenylpropyl] - 2 - azabicyclo [2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus.
Mackerer CR; Brougham LR; East PF; Bloss JL; Dajani EZ; Clay GA
J Pharmacol Exp Ther; 1977 Dec; 203(3):527-38. PubMed ID: 200732
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between opiate-like and antidiarrheal activities of antidiarrheal drugs.
Niemegeers CJ; McGuire JL; Heykants JJ; Janssen PA
J Pharmacol Exp Ther; 1979 Sep; 210(3):327-33. PubMed ID: 480185
[TBL] [Abstract][Full Text] [Related]
11. Effect of loperamide and naloxone on gastric acid secretion in healthy man.
Caldara R; Cambielli M; Masci E; Guslandi M; Barbieri C; Ferrari C
Gut; 1981 Sep; 22(9):720-3. PubMed ID: 7297919
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Electropharmacological Effects of Antidiarrheal Drug Loperamide and Its Antidote Naloxone in Anesthetized Guinea Pigs.
Takahara A; Izawa S; Seki S; Aimoto M; Nagasawa Y
Biol Pharm Bull; 2022; 45(4):542-546. PubMed ID: 35370282
[TBL] [Abstract][Full Text] [Related]
13. Dependence potential of loperamide studied in rhesus monkeys.
Yanagita T; Miyasato K; Sato J
NIDA Res Monogr; 1979; 27():106-13. PubMed ID: 121326
[No Abstract] [Full Text] [Related]
14. Oral naloxone antagonizes loperamide-induced delay of orocecal transit.
Basilisco G; Camboni G; Bozzani A; Paravicini M; Bianchi PA
Dig Dis Sci; 1987 Aug; 32(8):829-32. PubMed ID: 3608730
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and pharmacokinetics of nufenoxole in animals and humans: an example of stereospecific hydroxylation of an isoquinuclidine ring.
Cook CS; Campion JG; Hribar JD; Karim A
Xenobiotica; 1990 Oct; 20(10):1065-80. PubMed ID: 2082596
[TBL] [Abstract][Full Text] [Related]
16. Loperamide, the "Poor Man's Methadone": Brief Review.
Stanciu CN; Gnanasegaram SA
J Psychoactive Drugs; 2017; 49(1):18-21. PubMed ID: 27918873
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of SC-27166: a novel antidiarrheal agent.
Dajani EZ; Bianchi RG; East PF; Bloss JL; Adelstein GW; Yen CH
J Pharmacol Exp Ther; 1977 Dec; 203(3):512-26. PubMed ID: 411912
[TBL] [Abstract][Full Text] [Related]
18. Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk.
Lee VR; Vera A; Alexander A; Ruck B; Nelson LS; Wax P; Campleman S; Brent J; Calello DP
Clin Toxicol (Phila); 2019 Mar; 57(3):175-180. PubMed ID: 30585509
[TBL] [Abstract][Full Text] [Related]
19. Loperamide dependence and abuse.
MacDonald R; Heiner J; Villarreal J; Strote J
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25935922
[TBL] [Abstract][Full Text] [Related]
20. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers.
Schuermans V; Van Lommel R; Dom J; Brugmans J
Arzneimittelforschung; 1974 Oct; 24(10):1653-7. PubMed ID: 4611432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
